Study will assess the safety and effectiveness of 12 week treatment with the study medication, Bronchitol, in subjects with bronchiectasis (a lung disease where patients have trapped, and often infected, thick, sticky mucus). Past studies have shown Bronchitol inhalation may help to facilitate the clearance of mucus by altering its rheology (making it less thick and sticky), thereby enhancing the shift of stagnant mucus from the lungs. On completion of the double blind phase, subjects will have the opportunity to participate in a 52 week open label phase.

Inclusion Criteria:

• Non cystic fibrosis bronchiectasis
• Have FEV1 50% - 80% predicted and ≥1.0L
• Have chronic sputum production of >10 mL per day on the majority of days in the 3 months prior to study entry

Exclusion Criteria:

• Be using hypertonic saline or mucolytic pharmacological agents concurrently or in the 4 weeks prior to study entry
• Have airway hyperresponsiveness as defined by a positive Aridol challenge